BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

As emerging therapeutic modalities move toward mainstream, a flood of new companies has arisen to break through the limitations of first-generation technologies and expand the reach of gene and cell therapies,...
BioCentury | Jan 20, 2021
Product Development

Gritstone sending a mixed-modality COVID vaccine to Phase I

NIAID and the Gates Foundation are betting Gritstone’s antigen delivery and T cell epitope prediction technologies can yield a COVID-19 vaccine with both potent CD8+ T cell immunity and neutralizing antibody...
BioCentury | Jan 14, 2021
Finance

With €127M series B, cancer vaccine developer IO Biotech raises second-largest European venture round in the past year

...seed investment from Novo Seeds, and in 2016 raised €19.5 million in a series A.The company’s peptide...
...as monotherapy in patients with basal cell carcinoma.The company is also developing IO112, an ARG1-targeted peptide...
BioCentury | Jan 12, 2021
Product Development

Lilly’s amyloid therapy not a big step forward from Biogen’s

...lengths of and modifications to the amyloid peptide.Many...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...that could treat stroke —a cell-penetrating peptide...
...function in cystic fibrosis, and a cell-penetrating peptide...
...has also been filed for the FMR1 peptide...
BioCentury | Jan 1, 2021
Product Development

Not done yet. The COVID R&D Alliance has plenty on its plate for 2021

...zilucoplan from UCB Pharma S.A., a macrocyclic peptide...
BioCentury | Dec 31, 2020
Emerging Company Profile

Cardior: targeting microRNAs to treat heart failure

...O3miR-132 – MicroRNA-132 NT-proBNP – N-terminal pro-brain natriuretic peptide Danielle...
...Pharmaceuticals GmbH Hannover Medical School MicroRNA-132 (miR-132) N-terminal pro-brain natriuretic peptide...
BioCentury | Dec 31, 2020
Distillery Therapeutics

Agonizing adiponectin receptors to treat NASH, liver fibrosis

...could treat NASH and liver fibrosis. Chemical synthesis of analogs of adiponectin’s globular domain yielded a peptide...
...in liver cell lines. In a mouse model of NASH induced by a high-fat diet, the peptide...
...size, histological markers liver inflammation and steatosis, and serum levels of liver injury marker ALT. The peptide...
BioCentury | Dec 31, 2020
Deals

Dec. 30 Quick Takes: COVAXX-Aurobindo and Moderna-Recipharm in COVID deals; plus United-Y-mAbs, Zai-Cullinan and Incyte-Cellenkos

...will supply the bulk product for the peptide...
BioCentury | Dec 21, 2020
Translation in Brief

Reversible control of CAR expression; plus an inflammation-reducing mAb, two intranasal COVID-19 treatments and more

...the phenotypes.NeuBase compound rescues mis-splicing in myotonic dystrophy modelsNeuBase Therapeutics Inc. (NASDAQ:NBSE) said its preclinical peptide...
Items per page:
1 - 10 of 8893
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

As emerging therapeutic modalities move toward mainstream, a flood of new companies has arisen to break through the limitations of first-generation technologies and expand the reach of gene and cell therapies,...
BioCentury | Jan 20, 2021
Product Development

Gritstone sending a mixed-modality COVID vaccine to Phase I

NIAID and the Gates Foundation are betting Gritstone’s antigen delivery and T cell epitope prediction technologies can yield a COVID-19 vaccine with both potent CD8+ T cell immunity and neutralizing antibody...
BioCentury | Jan 14, 2021
Finance

With €127M series B, cancer vaccine developer IO Biotech raises second-largest European venture round in the past year

...seed investment from Novo Seeds, and in 2016 raised €19.5 million in a series A.The company’s peptide...
...as monotherapy in patients with basal cell carcinoma.The company is also developing IO112, an ARG1-targeted peptide...
BioCentury | Jan 12, 2021
Product Development

Lilly’s amyloid therapy not a big step forward from Biogen’s

...lengths of and modifications to the amyloid peptide.Many...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...that could treat stroke —a cell-penetrating peptide...
...function in cystic fibrosis, and a cell-penetrating peptide...
...has also been filed for the FMR1 peptide...
BioCentury | Jan 1, 2021
Product Development

Not done yet. The COVID R&D Alliance has plenty on its plate for 2021

...zilucoplan from UCB Pharma S.A., a macrocyclic peptide...
BioCentury | Dec 31, 2020
Emerging Company Profile

Cardior: targeting microRNAs to treat heart failure

...O3miR-132 – MicroRNA-132 NT-proBNP – N-terminal pro-brain natriuretic peptide Danielle...
...Pharmaceuticals GmbH Hannover Medical School MicroRNA-132 (miR-132) N-terminal pro-brain natriuretic peptide...
BioCentury | Dec 31, 2020
Distillery Therapeutics

Agonizing adiponectin receptors to treat NASH, liver fibrosis

...could treat NASH and liver fibrosis. Chemical synthesis of analogs of adiponectin’s globular domain yielded a peptide...
...in liver cell lines. In a mouse model of NASH induced by a high-fat diet, the peptide...
...size, histological markers liver inflammation and steatosis, and serum levels of liver injury marker ALT. The peptide...
BioCentury | Dec 31, 2020
Deals

Dec. 30 Quick Takes: COVAXX-Aurobindo and Moderna-Recipharm in COVID deals; plus United-Y-mAbs, Zai-Cullinan and Incyte-Cellenkos

...will supply the bulk product for the peptide...
BioCentury | Dec 21, 2020
Translation in Brief

Reversible control of CAR expression; plus an inflammation-reducing mAb, two intranasal COVID-19 treatments and more

...the phenotypes.NeuBase compound rescues mis-splicing in myotonic dystrophy modelsNeuBase Therapeutics Inc. (NASDAQ:NBSE) said its preclinical peptide...
Items per page:
1 - 10 of 8893